TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD
Brief Summary: This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder


Options:
A: Arm Label: Ritalin LA; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release) | Intervention Type: DRUG; Name: Ritalin LA (methylphenidate hydrochloride extended release); Assigned to Arm(s): Ritalin LA
B: Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001
D: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD
Brief Summary: This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder


Options:
A: Arm Label: Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsule, Drug: Placebo | Arm Label: Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsule, Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsule; Assigned to Arm(s): Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo), Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo), Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): 1
C: Arm Label: Methylphenidate, Dexamphetamine, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate, Drug: Placebo, Drug: Dextroamphetamine | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo
D: Arm Label: Ritalin LA; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release) | Intervention Type: DRUG; Name: Ritalin LA (methylphenidate hydrochloride extended release); Assigned to Arm(s): Ritalin LA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD
Brief Summary: This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System (MTS) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo patch | Intervention Type: DRUG; Name: Methylphenidate Transdermal System (MTS); Assigned to Arm(s): A | Intervention Type: OTHER; Name: placebo patch; Assigned to Arm(s): B
B: Arm Label: Adhansia XR; Type: EXPERIMENTAL; Interventions: Drug: Adhansia XR | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Adhansia XR; Assigned to Arm(s): Adhansia XR | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
C: Arm Label: Ritalin LA; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release) | Intervention Type: DRUG; Name: Ritalin LA (methylphenidate hydrochloride extended release); Assigned to Arm(s): Ritalin LA
D: Arm Label: Medication Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vyvanse, Drug: Methylphenidate | Arm Label: Behavioral Parent Training Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Parent Training | Intervention Type: DRUG; Name: Vyvanse; Assigned to Arm(s): Medication Arm | Intervention Type: BEHAVIORAL; Name: Behavioral Parent Training; Assigned to Arm(s): Behavioral Parent Training Arm | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medication Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delivered Dietary Intervention for Children With Irritable Bowel Syndrome
Brief Summary: The purpose of this study is to determine whether a specific diet may help children with irritable bowel syndrome.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG (probiotic ) | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG (probiotic ); Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: High fermentable substrate diet; Type: EXPERIMENTAL; Interventions: Other: High fermentable substrate diet | Arm Label: Low fermentable substrate diet; Type: EXPERIMENTAL; Interventions: Other: Low fermentable substrate diet | Intervention Type: OTHER; Name: Low fermentable substrate diet; Assigned to Arm(s): Low fermentable substrate diet | Intervention Type: OTHER; Name: High fermentable substrate diet; Assigned to Arm(s): High fermentable substrate diet
C: Arm Label: Probiotics supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Glucomannan; Type: EXPERIMENTAL; Interventions: Drug: Glucomannan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Glucomannan; Assigned to Arm(s): Glucomannan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparo-endoscopic Single Site Cholecystectomy Versus Standard Laparoscopic Cholecystectomy
Brief Summary: The aim of this study is to assess possible differences between the LESS approach and the standard laparoscopic approach to cholecystectomy. In particular, the Postoperative Quality of Life (QoL) will be investigated by analyzing the followings: length of hospital stay (LoS), postoperative pain, cosmetics and the results of SF 36 questionnaire. Furthermore, operative time, conversion to standard LC rate, difficulty of exposure, difficulty of dissection, and complication rate will be compared.


Options:
A: Arm Label: Single port laparoscopic device; Type: EXPERIMENTAL; Interventions: Device: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa) | Arm Label: Four-port laparoscopic device; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Four port laparoscopic cholecystectomy surgery | Intervention Type: DEVICE; Name: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa); Assigned to Arm(s): Single port laparoscopic device | Intervention Type: PROCEDURE; Name: Four port laparoscopic cholecystectomy surgery; Assigned to Arm(s): Four-port laparoscopic device
B: Arm Label: SILS Cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SILS | Arm Label: Standard Laparoscopic Cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Laparoscopic Cholecystectomy | Intervention Type: PROCEDURE; Name: SILS; Assigned to Arm(s): SILS Cholecystectomy | Intervention Type: PROCEDURE; Name: Standard Laparoscopic Cholecystectomy; Assigned to Arm(s): Standard Laparoscopic Cholecystectomy
C: Arm Label: LESS cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Arm Label: Standard LAP-CHOLE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Arm Label: LESS Cholecystectomy not blind; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Intervention Type: PROCEDURE; Name: Cholecystectomy; Assigned to Arm(s): LESS Cholecystectomy not blind, LESS cholecystectomy, Standard LAP-CHOLE
D: Arm Label: Laparoscopic Cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Cholecystectomy | Arm Label: SILS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SILS | Intervention Type: PROCEDURE; Name: Laparoscopic Cholecystectomy; Assigned to Arm(s): Laparoscopic Cholecystectomy | Intervention Type: PROCEDURE; Name: SILS; Assigned to Arm(s): SILS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy
Brief Summary: This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).


Options:
A: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy
Brief Summary: This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
B: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS
Brief Summary: This is a multi-centre, double blind, randomised, placebo controlled, parallel group, phase 4 pilot study investigating colecalciferol (vitamin D3) as an add-on treatment to subcutaneously administered interferon-beta-1b in relapsing-remitting multiple sclerosis patients.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol, Dietary Supplement: calcium carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium carbonate; Assigned to Arm(s): 1, 2
C: Arm Label: High dose vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Low dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): High dose vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Low dose vitamin D
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Colecalciferol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Colecalciferol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Introduction of Cholera Vaccine in Bangladesh: " Impact Evaluation of Cholera Vaccine and Behaviour Change Interventions in Urban Dhaka"
Brief Summary: The purpose of this study is to conduct and evaluate the feasibility and effectiveness of a mass cholera vaccination program to reduce diarrhea due to Vibrio cholerae in a high incidence urban area. This study will also evaluate the feasibility of adding a household hand washing and safe drinking water promotion intervention to a cholera vaccine program and the overall impact of this combination on decreasing the incidence of diarrhea due to Vibrio cholerae.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli | Intervention Type: BIOLOGICAL; Name: killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rBS-WC vaccine | Intervention Type: BIOLOGICAL; Name: rBS-WC vaccine; Assigned to Arm(s): 1
C: Arm Label: Vaccine arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: ShanChol | Arm Label: Vaccine plus hygiene and safe water arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vaccine and behaviour | Arm Label: Non-intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: ShanChol; Assigned to Arm(s): Vaccine arm | Intervention Type: BEHAVIORAL; Name: Vaccine and behaviour; Assigned to Arm(s): Vaccine plus hygiene and safe water arm
D: Arm Label: Shanchol; Type: EXPERIMENTAL; Interventions: Biological: Shanchol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Shanchol; Assigned to Arm(s): Shanchol | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Introduction of Cholera Vaccine in Bangladesh: " Impact Evaluation of Cholera Vaccine and Behaviour Change Interventions in Urban Dhaka"
Brief Summary: The purpose of this study is to conduct and evaluate the feasibility and effectiveness of a mass cholera vaccination program to reduce diarrhea due to Vibrio cholerae in a high incidence urban area. This study will also evaluate the feasibility of adding a household hand washing and safe drinking water promotion intervention to a cholera vaccine program and the overall impact of this combination on decreasing the incidence of diarrhea due to Vibrio cholerae.


Options:
A: Arm Label: Hand sanitizer group; Type: EXPERIMENTAL; Interventions: Other: hand sanitizer | Arm Label: Liquid soap group; Type: EXPERIMENTAL; Interventions: Other: liquid soap | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: hand sanitizer; Assigned to Arm(s): Hand sanitizer group | Intervention Type: OTHER; Name: liquid soap; Assigned to Arm(s): Liquid soap group
B: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
C: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
D: Arm Label: Vaccine arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: ShanChol | Arm Label: Vaccine plus hygiene and safe water arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vaccine and behaviour | Arm Label: Non-intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: ShanChol; Assigned to Arm(s): Vaccine arm | Intervention Type: BEHAVIORAL; Name: Vaccine and behaviour; Assigned to Arm(s): Vaccine plus hygiene and safe water arm

Answer: D